Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
about
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.Immunotherapeutic implication of IL-6 blockade.Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases.
P2860
Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@en
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@nl
type
label
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@en
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@nl
prefLabel
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@en
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@nl
P2860
P356
P1476
Tocilizumab: molecular interve ...... juvenile idiopathic arthritis.
@en
P2093
Shumpei Yokota
Tadamitsu Kishimoto
P2860
P304
P356
10.1586/ECI.10.41
P577
2010-09-01T00:00:00Z